Finasteride helped users feel better about hair loss, with some experiencing positive changes in confidence and reduced anxiety. Despite initial concerns, users reported satisfaction with the treatment over several months.
Dutasteride users have mixed results in hair loss treatment, with some experiencing improvements and others worsening. Some report metabolic changes like weight gain or diabetes, while others have no significant side effects.
Pyrilutamide/KX-826 is being discussed for its effectiveness in hair regrowth, with some users reporting positive results, especially in early hair loss cases. Users have combined it with treatments like Minoxidil, and some experienced initial shedding before seeing regrowth.
The user is experiencing irritation from using PG with RU58841 and is seeking alternative solutions like K&B in the UK. They report redness, itchiness, and flaky skin from the current treatment.
High dose topical Finasteride solutions are speculative and not proven more effective than low dose solutions. Users report varying results with different concentrations, with some preferring lower doses to minimize side effects.
Adding RU58841 to Dutasteride treatment helped reduce hair shedding significantly for several users. Some reported no change with RU58841, while others experienced a dramatic decrease in shedding and increased hair density.
Topical tretinoin applied to the face may exacerbate hair loss in some individuals, potentially triggering conditions like frontal fibrosing alopecia. Experiences vary, with some users reporting no impact on hair, while others experience significant hair loss.
The conversation discusses interest in peptides for hair loss, specifically mentioning ahkCU and ghkCU. A user is considering adding ghkCU to their treatment regimen.
The user plans to pause finasteride for two months to test its effects on mood and productivity, then switch to Pyrilutamide while monitoring hormone levels. Concerns are raised about potential hair loss and the effectiveness of Pyrilutamide compared to finasteride.
The conversation is about the effectiveness of topical melatonin for hair loss. The user is asking about the duration and results of using this treatment.
The conversation discusses the absorption and effectiveness of PG-free versus PG versions of RU58841, with some users believing PG improves efficacy while others see no difference. Concerns about RU58841's potential side effects on the endocrine system are also mentioned, with one user considering switching to pyrilutamide.
A user received a prescription for Dutasteride 0.5 in Europe and asked about the brand. Replies confirmed the brand's quality and suggested using the cheapest gelatin capsule form.
The user experienced no significant improvement in hair loss despite using Dutasteride, oral Minoxidil, and previously RU58841, and is uncertain if changes in medication or stopping RU58841 worsened the condition. Some users noted no change or slight improvement, while others suggested the possibility of Dutasteride causing issues.
User added RU58841 to their hair loss treatment and experienced quick results. Others also reported positive effects, but one user experienced chest pains as a side effect.
The conversation discusses finasteride for hair loss, especially among those with a history of depression. Users shared mixed experiences, with some reporting no issues and others experiencing worsened depression.
The conversation discusses using topical finasteride for hair loss, with concerns about its safety around family members, especially pregnant women and infants. One user plans to try topical finasteride due to side effects from the pill.
Extended-release oral minoxidil (VDPHL01) shows promising results for hair growth with improved safety, achieving significant hair count increases and minimal side effects compared to placebo. The treatment is designed to maintain effective concentrations while reducing side effects, making it a safer option for those who cannot tolerate standard minoxidil.
A new topical medication, Clascoterone, shows promise for hair loss, improving hair count significantly. Trials for Breezula are ending, but sign-ups for PP405 trials are available for 2026.
The conversation is about finding a clearnet vendor for clascoterone, also known as Winlevi, for hair loss treatment. The user is seeking recommendations via direct message.
A 20-year-old with anxiety and depression is considering finasteride for hair loss but is worried about potential side effects. They decide to consult a doctor and consider starting with a low dose, while also exploring topical finasteride as a potentially safer option.
RU58841 is used without finasteride by some due to side effects, with mixed results. Users report combining RU58841 with minoxidil and adjusting finasteride doses to manage hair loss.
The user shared progress after two months using a topical formulation containing Dutasteride 0.25%, Minoxidil 5%, Cetirizine 1%, Melatonin 0.5%, Caffeine 2%, and Latanoprost 0.005%. The focus is on hair loss treatment results.
The conversation is about seeking user experiences with Traya for hair loss treatment, focusing on the effectiveness and convenience of its doctor, diet, and product approach. The user is conducting research and requests feedback on what worked or didn't work.
The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.
The user is considering making a homemade topical finasteride solution using an ethanol-based carrier. They are inquiring if a solution containing partially denatured ethyl alcohol and benzalkonium chloride is suitable.
A user shared their experience with hair loss treatments, using minoxidil, pyrilutamide, alfatrodial, and nizoral to improve hair density and thickness. They reported positive results without side effects and emphasized the importance of consistency with topical treatments.
The conversation is about when the phase 3 results for pyrilutamide, a potential hair loss treatment, will be released. There was a letter about the study a month ago, but the actual results were not included.